A summary in the April 12 edition of DiabetesPro SmartBrief gave the incorrect name of the drug that showed the lowest risk of new-onset diabetes for participants in a meta-analysis. The name of the drug is pravastatin. SmartBrief regrets the error.
Data presented at the World Diabetes Congress revealed patients with new-onset type 2 diabetes who underwent bariatric surgery maintained greater remission rates at two, 10 and 15 years compared with those who had diabetes for more than three years at baseline. Researchers also found patients with longer disease duration did not show significant improvements in diabetes complication rates following surgery compared with those who only received medical care.
Canadian researchers found atorvastatin was associated with a 22% increased risk of new-onset diabetes, while patients who took rosuvastatin or simvastatin had an 18% and 10% increased risk of the condition, respectively, compared with patients taking pravastatin. Pravastatin, fluvastatin and lovastatin were tied to a slightly lower diabetes risk, researchers reported in BMJ.
A study presented at the annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons showed morbidly obese patients who either had robotic sleeve gastrectomy or robotic gastric bypass attained similar weight loss, and mean hospitalization times were 2.2 days for both groups. Complications were low, but researchers said more studies are needed to back the findings.
A study in the journal Pediatrics showed between 30% and 40% of parents said they urge their children to continue eating even after they said they are full. Parents of teens who were not overweight were more likely to display pressure-to-eat behaviors than parents of overweight and obese teens, researchers said. "Parental pressure to eat can be detrimental to children because it takes away from a child's ability to respond naturally to their own hunger," lead author Katie Loth said.
Participants taking plavastatin showed the lowest risk of new-onset diabetes, while atorvastatin and rosuvastatin were associated with intermediate and higher risk, compared with people in a placebo group, a meta-analysis in The American Journal of Cardiology revealed.